Advertisement
UK markets open in 3 hours 41 minutes

  • NIKKEI 225

    38,090.87
    +129.07 (+0.34%)
     

  • HANG SENG

    16,495.95
    +244.11 (+1.50%)
     

  • CRUDE OIL

    82.81
    +0.12 (+0.15%)
     

  • GOLD FUTURES

    2,388.30
    -0.10 (-0.00%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,752.23
    -1,586.82 (-3.09%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

Exploring the Financial Performance of Akcea Therapeutics

Kenneth Smith
Updated
Exploring the Financial Performance of Akcea Therapeutics

The company generated this revenue from research and development under a collaboration agreement with Novartis (NVS). In 2018, Akcea Therapeutics is expected to generate revenue of $71.3 million, while its peers Amgen (AMGN), Ionis Pharmaceuticals (IONS), and bluebird bio (BLUE) are expected to generate revenues of $22.5 billion, $582.4 million, and $23.9 million, respectively. In 2017, Akcea Therapeutics incurred research and development expenses of $126.8 million compared to $68.4 million in 2016.

Continue reading